Select Publications


Boyd K et al. Does zoledronic acid reduce skeletal-related events and improve progression-free survival in patients with multiple myeloma with or without bone disease? MRC Myeloma IX study results. Proc ASCO 2011;Abstract 8010.

Davies F et al. Are there benefits to long-term bisphosphonate treatment in multiple myeloma (MM)? Insights from temporal analyses of zoledronic acid (ZOL) versus clodronate (CLO) in the MRC Myeloma IX trial. Proc ASCO 2011;Abstract 8011.


Phase 3 study comparing carfilzomib, lenalidomide, and dexamethasone (CRd) versus lenalidomide and dexamethasone (Rd) in subjects with relapsed multiple myeloma. NCT01080391.

Randomized trial of lenalidomide, bortezomib, dexamethasone vs high-dose treatment with SCT in MM patients up to age 65 (IFM/DFCI2009). NCT01208662.